Helmholtz Gemeinschaft


Characterization and modulation of anti- αβTCR antibodies and their respective binding sites at the βTCR chain to enrich engineered T cells

PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
[img] Other (Supplementary Material)

Item Type:Article
Title:Characterization and modulation of anti- αβTCR antibodies and their respective binding sites at the βTCR chain to enrich engineered T cells
Creators Name:Kierkels, G.J.J. and van Diest, E. and Hernández-López, P. and Scheper, W. and de Bruin, A.C.M. and Frijlink, E. and Aarts-Riemens, T. and van Dooremalen, S.F.J. and Beringer, D.X. and Oostvogels, R. and Kramer, L. and Straetemans, T. and Uckert, W. and Sebestyén, Z. and Kuball, J.
Abstract:T cell engineering strategies offer cure to patients and entered clinical practice with chimeric antibody-based receptors, αβT cell receptors (αβTCR)-based strategies are however lagging behind. To allow a more rapid and successful translation to successful concepts also using αβTCRs for engineering, incorporating a method for the purification of genetically modified T cells, as well as engineered T cell deletion after transfer into patients, could be beneficial. This would allow to increase efficacy, reduce potential side effects, and improve safety of newly, to be tested, lead structures. By characterizing the antigen binding interface of a GMP-grade anti-αβTCR antibody, usually used for depletion of αβT cells from stem cell transplantation products, we developed a strategy which allows for the purification of untouched αβTCR engineered immune cells by changing two amino acids only in the TCR β chain constant domain of introduced TCR chains. Vice versa, we engineered an antibody, which targets an extended mutated interface of nine amino acids in the TCR β chain constant domain, and provides the opportunity to further develop depletion strategies of engineered immune cells.
Keywords:Immunotherapy, T Cell Engineering, Select-Kill Strategy, Epitope Mapping, T Cell Depletion, Animals, Mice, Rats
Source:Molecular Therapy - Methods and Clinical Development
Publisher:Cell Press
Page Range:388-400
Date:10 September 2021
Official Publication:https://doi.org/10.1016/j.omtm.2021.06.011
PubMed:View item in PubMed

Repository Staff Only: item control page


Downloads per month over past year

Open Access
MDC Library